Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial "DASH"

Not yet recruiting

Phase 1/2 Results N/A

Eligibility Criteria

Inclusion Criteria

- subarachnoid hemorrhage diagnosed by CT on admission,
- Randomizable within 72 hours of subarachnoid hemorrhage,
- Saccular intracranial aneurysm proven by cerebral angiography or CTA,
- Surgical or endovascular obliteration is performed,
- Able to obtain written informed consent from patient or surrogate.
- Patients in a good clinical grade (WFNS 1-3)

Exclusion Criteria

- Pregnancy, as confirmed by routine urine test on admission,
- Abnormal renal function at time of randomization (GFR <60 mL/min)
- Elevated liver function test at time of randomization (AST > 45 U/L and ALT > 35 U/L.)
- History of liver disease or active liver disease, Active renal disease,
- Hypersensitivity to deferoxamine,
- Patient taking medication not recommended for concomitant use with deferoxamine as per the product label (e.g. high dose vit. C medication).
- Patients not able to complete the study follow-up the presence of 4 or more of the following exclusion criteria (risk modifiers for ARDS):
- Tachypnea (respiratory rate >30)
- SpO2 <95%
- Obesity (BMI >30)
- Acidosis (pH <7.35)
- Hypoalbuminemia (albumin <3.5 g/dL)
- concurrent use of chemotherapy